# Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion

> **NCT01030952** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 103 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Nateglinide
- **DRUG:** Acarbose

## Key facts

- **NCT ID:** NCT01030952
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2012-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01030952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01030952, "Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01030952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*